Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.72 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.72 |
| ▸ | CNR1 | P21554 | 10/20 | 0.70 |
| ▸ | CNR2 | P34972 | 7/20 | 0.70 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.70 |
| ▸ | CASR | P41180 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3172518 | 0.89 | MTNR1A (0.59) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL31505725 | 0.88 | HTR2A (0.58) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL4219824 | 0.84 | MTNR1A (1.00) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL5841117 | 0.84 | MTNR1A (0.68) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL3642993 | 0.84 | MTNR1A (0.68) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL3510106 | 0.84 | MTNR1A (0.53) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL1426449 | 0.82 | MTNR1A (0.56) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL3505478 | 0.82 | MTNR1A (0.51) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL2427167 | 0.82 | CNR1 (0.70) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL5948102 | 0.82 | EPHX2 (1.00) | MTNR1AMTNR1BCNR1CNR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249128-B2 | Anti-cancer serine hydrolase inhibitory carbamates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-02-02 | — | — | US | disclosed |
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| EP-2632912-A2 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | The Scripps Research Institute (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012058115-A2 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | CRAVATT BENJAMIN (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | AADAC, DDAH1, PRSS1 | MTNR1A 3983/4885MTNR1B 4217/4885CNR1 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.